(Steele et al., 2009). Typically, in chemoresistant ovarian cancer,RGS10is responsible for ovarian cancer cell growth and survival but is usually suppressed. However, it was reversely upregulated by dual inhibition ofDNMTandHDACenzymes, and the toxicity ofcisplatinwas enhanced (Ali et al., ...
The function and potentially compensatory or opposing roles of NOTCH proteins have not yet been well delineated in bladder cancer. For example: studies show that NOTCH1 is oncogenic and increases cell proliferation and invasive potential of bladder cancer cells in vitro 48,49. These studies used ...
Xia C, Leon-Ferre R, Laux D, Deutsch J, Smith BJ, Frees M, et al. Treatment of resistant metastatic melanoma using sequential epige- netic therapy (decitabine and panobinostat) combined with chemo- therapy (temozolomide). Cancer Chemother Pharmacol 2014;74: 691-7....
Thirteen pts (22%) had prior MDS (4 pts prior azacitidine; 2 pts prior lenalidomide) and 17 pts (29%) had secondary AML (Hx of prior chemo and/or XRT). Of 57 pts evaluable for response, 35 (61%) achieved CR and 4 (7%) CRp for an ORR of 68%. Six pts (11%) required more...